Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.
Kappos L, Wolinsky JS, Giovannoni G, Arnold DL, Wang Q, Bernasconi C, Model F, Koendgen H, Manfrini M, Belachew S, Hauser SL. Kappos L, et al. Among authors: koendgen h. JAMA Neurol. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. JAMA Neurol. 2020. PMID: 32511687 Free PMC article. Clinical Trial.
Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension.
Hauser SL, Kappos L, Arnold DL, Bar-Or A, Brochet B, Naismith RT, Traboulsee A, Wolinsky JS, Belachew S, Koendgen H, Levesque V, Manfrini M, Model F, Hubeaux S, Mehta L, Montalban X. Hauser SL, et al. Among authors: koendgen h. Neurology. 2020 Sep 29;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376. Epub 2020 Jul 20. Neurology. 2020. PMID: 32690791 Free PMC article.
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL. Wolinsky JS, et al. Among authors: koendgen h. Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29. Lancet Neurol. 2020. PMID: 33129442 Clinical Trial.
Risk of requiring a walking aid after 6.5 years of ocrelizumab treatment in patients with relapsing multiple sclerosis: Data from the OPERA I and OPERA II trials.
Giovannoni G, Kappos L, de Seze J, Hauser SL, Overell J, Koendgen H, Manfrini M, Wang Q, Wolinsky JS. Giovannoni G, et al. Among authors: koendgen h. Eur J Neurol. 2022 Apr;29(4):1238-1242. doi: 10.1111/ene.14823. Epub 2021 May 5. Eur J Neurol. 2022. PMID: 33724637 Free PMC article. Clinical Trial.
Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L. Hauser SL, et al. Among authors: koendgen h. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(2):e200094. doi: 10.1212/NXI.0000000000200094. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36792367 Free PMC article. Clinical Trial.
Blood neurofilament light levels predict non-relapsing progression following anti-CD20 therapy in relapsing and primary progressive multiple sclerosis: findings from the ocrelizumab randomised, double-blind phase 3 clinical trials.
Bar-Or A, Thanei GA, Harp C, Bernasconi C, Bonati U, Cross AH, Fischer S, Gaetano L, Hauser SL, Hendricks R, Kappos L, Kuhle J, Leppert D, Model F, Sauter A, Koendgen H, Jia X, Herman AE. Bar-Or A, et al. Among authors: koendgen h. EBioMedicine. 2023 Jul;93:104662. doi: 10.1016/j.ebiom.2023.104662. Epub 2023 Jun 22. EBioMedicine. 2023. PMID: 37354600 Free PMC article. Clinical Trial.
Ocrelizumab exposure in relapsing-remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension.
Kappos L, Traboulsee A, Li DKB, Bar-Or A, Barkhof F, Montalban X, Leppert D, Baldinotti A, Schneble HM, Koendgen H, Sauter A, Wang Q, Hauser SL. Kappos L, et al. Among authors: koendgen h. J Neurol. 2024 Feb;271(2):642-657. doi: 10.1007/s00415-023-11943-4. Epub 2023 Oct 31. J Neurol. 2024. PMID: 37906326 Free PMC article.
Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis.
Abdelhak A, Antweiler K, Kowarik MC, Senel M, Havla J, Zettl UK, Kleiter I, Hoshi MM, Skripuletz T, Haarmann A, Stahmann A, Huss A, Gingele S, Krumbholz M, Selge C, Friede T, Ludolph AC, Overell J, Koendgen H, Clinch S, Wang Q, Ziemann U, Hauser SL, Kümpfel T, Green AJ, Tumani H. Abdelhak A, et al. Among authors: koendgen h. Mult Scler Relat Disord. 2024 Jan;81:105139. doi: 10.1016/j.msard.2023.105139. Epub 2023 Nov 18. Mult Scler Relat Disord. 2024. PMID: 38000130 Free article.
22 results